What counts as a correlate of protection
Stanley A. Plotkin, University of Pennsylvania, framed correlates of protection as measurable immune markers that predict vaccine-mediated defense. For most licensed vaccines the simplest and most practical correlate is antibody level because it is measurable and often directly linked to prevention of infection. However, not every marker predicts all clinical outcomes equally; preventing infection, symptomatic disease, and severe disease can require different immune features.
Immune markers with the strongest predictive value
Neutralizing antibodies are the clearest single predictor of short- to mid-term protection against many viral infections; they block entry and are routinely used to compare vaccine responses. Long-lived plasma cells in bone marrow and circulating memory B cells underlie the durability of antibody-mediated protection by sustaining or rapidly regenerating neutralizing titers after exposure. Shane Crotty, La Jolla Institute for Immunology, has highlighted the role of T follicular helper CD4 T cells in forming durable germinal center responses that produce high-quality memory B cells. For protection against severe disease when sterilizing immunity wanes, CD8 cytotoxic T cells and helper CD4 responses are more strongly linked to reduced disease severity, a point emphasized in reviews and experimental studies. Akiko Iwasaki, Yale University, has stressed the importance of tissue-resident memory and mucosal IgA for respiratory pathogens where local immunity can prevent transmission and early replication.
Relevance, causes, and consequences
The predictive power of any marker depends on biological and contextual factors. Viral antigenic drift reduces the relevance of previously measured neutralizing antibodies, making variant-specific immune breadth and memory B cell cross-reactivity crucial. Age, comorbidities, prior infections, and nutritional or environmental exposures change immune memory quality and therefore the meaning of a given marker in different populations. In regions with limited vaccine access or frequent pathogen exposure, observed correlates may reflect hybrid immunity and differ from trial populations.
Using these markers to guide policy has clear consequences: reliable correlates let regulators approve modified vaccines more rapidly, inform booster timing, and prioritize vulnerable groups. Conversely, overreliance on single markers without considering T cell responses, mucosal immunity, and population context risks misestimating protection, with implications for outbreak control, equitable vaccine distribution, and long-term public health planning.